Deepti Bhasin, MD
Child & Adolescent Psychiatry · Warner Robins, GANPI 1285717942
Payments from drug & device makers
Across 614 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Lundbeck LLC$1K
- Teva Pharmaceuticals USA, Inc.$999
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$820
- Ironshore Pharmaceuticals Inc.$784
- plus $5K from 28 others
What the payments were for
- Food & beverage$10,86796%
- Education$4564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 72 | $1,285 |
| AbbVie(2 entities) | 75 | $1,249 |
| Lundbeck LLC | 56 | $1,099 |
| Teva Pharmaceuticals USA, Inc. | 40 | $999 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $820 |
| Ironshore Pharmaceuticals Inc. | 46 | $784 |
| Johnson & Johnson | 39 | $779 |
| Neurocrine Biosciences, Inc. | 26 | $600 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $599 |
| Alkermes, Inc. | 29 | $531 |
| Supernus Pharmaceuticals, Inc. | 26 | $405 |
| Tris Pharma Inc | 18 | $282 |
| Corium, LLC | 11 | $276 |
| Vanda Pharmaceuticals Inc. | 14 | $269 |
| Neos Therapeutics, LP | 13 | $231 |
| Collegium Pharmaceutical, Inc. | 11 | $199 |
| Avanir Pharmaceuticals, Inc. | 10 | $171 |
| E.r. Squibb & Sons, L.L.C. | 5 | $111 |
| Eisai Inc. | 6 | $100 |
| Neuronetics, Inc. | 6 | $92 |
| Shire North American Group Inc | 4 | $69 |
| Adlon Therapeutics L.p. | 4 | $68 |
| Noven Therapeutics, LLC | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Merck | 2 | $33 |
| Bausch Health US, LLC | 2 | $27 |
| Biogen | 1 | $23 |
| Brainsway USA Inc | 1 | $17 |
| Tempus AI, Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Orexo US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$113
How this compares
$11,323 in reported general payments places this provider in the 90th percentile of 91 child & adolescent psychiatry providers in Georgia.
See all child & adolescent psychiatry providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 79 | $664,448 |
| VraylarCariprazine Hcl | 110 | $177,066 |
| RexultiBrexpiprazole | 92 | $167,657 |
| AustedoDeutetrabenazine | 25 | $146,913 |
| Invega SustennaPaliperidone Palmitate | 35 | $68,284 |
| Abilify MaintenaAripiprazole | 23 | $54,443 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $49,052 |
| TrintellixVortioxetine Hydrobromide | 33 | $26,416 |
| Aripiprazole | 364 | $20,812 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 256 | $13,770 |
| BelsomraSuvorexant | 19 | $10,197 |
| Quetiapine Fumarate | 608 | $9,819 |
| Duloxetine Hcl | 449 | $8,784 |
| Buspirone Hcl | 564 | $8,424 |
| Bupropion XlBupropion Hcl | 374 | $6,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $600 | $664,44879 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,285 | $222,100115 claims |
| AbbVieVraylar | $1,249 | $177,066110 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $999 | $146,91325 claims |
| Johnson & JohnsonInvega Sustenna | $779 | $68,28435 claims |
| Alkermes, Inc.Lybalvi | $531 | $49,05232 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $599 | $26,41633 claims |
| MerckBelsomra | $33 | $10,19719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 91 child & adolescent psychiatry providers in Georgia.
Other child & adolescent psychiatry in Warner Robins
- Suneel KatragaddaAtlanta$2.1M
- Kevin WindersSavannah$225K
- Olufemi TaiwoFayetteville$173K
- Annamarie PaulsenConyers$25K
- Haolat BabalakinBerkeley Lake$16K
- Heerain ShahSuwanee$14K
- Olujimi AdefisanAtlanta$14K
- Mhd AlkhatibAtlanta$7K
- Mary HuberAtlanta$7K
- Jocelyn BaylissAugusta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.